Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine

 Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine

Shots:

  • HilleVax gets an exclusive license for the development and commercialization rights of Takeda’s HIL-214 globally (Ex-Japan). Takeda will hold the commercialization rights of the vaccine in Japan
  • Takeda will focus primarily on dengue, COVID-19, pandemic influenza and Zika vaccines. HilleVax will merge Japan development activities into its global development
  • HIL-214 is a VLP based vaccine that has completed a P-IIb efficacy study in 4,712 adults, demonstrated clinical POC in preventing mod. to sev. acute gastroenteritis from norovirus infection. The vaccine was well-tolerated

Click here to  to read full press release/ article | Ref: GlobeNewswire | Image: GeneOnline

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post